title: [Prevalence of Plasmodium falciparum, anemia and molecular markers of chloroquine and sulfadoxine-pyriméthamine resistance in delivered women in Fana, Mali].
abstract: The aim of this study was to describe the malaria morbidity and the frequencies of molecular markers of resistance to chloroquine and sulfadoxine-pyrimethamine in pregnant women at delivery in Mali. Two hundred pregnant women have been included at the delivery clinic in Fana. The age group of 14-19 years was predominant. Fifty two per cent (52.3%: 104/200) were malaria slides positive in their peripheral blood and 15% (30/200) of the women carried parasite in their placenta. The prevalence rate of anemia was 44.5% (89/200). PCR technique was successfully performed on 16 paired samples. The frequency of the Pfcrt K76T mutants in Plasmodium falciparum infections in peripheral blood was 68.8% (11/16) and 100% (16/16) in the placenta (p = 0.004). The frequency in peripheral blood of the DHFR N51I mutation was 12.5% (2/16) and 18.8% (3/16) in the placenta (p=0.12). The frequencies of the DHPS A437G mutants were similar in both sites 25% (4/16). No DHPS K540E and DHFR 164L mutations were found in the Fana pregnancy women samples.
authors.affiliation: Malaria Research and Training Center (MRTC), Mali. sdoumbo@icermali.org
authors.forename: S
authors.initials: S
authors.lastname: Doumbo
authors.forename: O A
authors.initials: OA
authors.lastname: Ongoiba
authors.forename: D
authors.initials: D
authors.lastname: Doumtabé
authors.forename: A
authors.initials: A
authors.lastname: Dara
authors.forename: T D
authors.initials: TD
authors.lastname: Ouologuem
authors.forename: K
authors.initials: K
authors.lastname: Kayentao
authors.forename: A
authors.initials: A
authors.lastname: Djimdé
authors.forename: B
authors.initials: B
authors.lastname: Traoré
authors.forename: O K
authors.initials: OK
authors.lastname: Doumbo
mesh_terms: D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000453:epidemiology* / Q000209:etiology; D002738:Chloroquine / Q000627:therapeutic use*; D036861:Delivery, Obstetric / Q000706:statistics & numerical data; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics*; D005260:Female; D005819:Genetic Markers; D006801:Humans; D016778:Malaria, Falciparum / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D008302:Mali / Q000453:epidemiology; D010963:Plasmodium falciparum; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy / Q000453:epidemiology; D015995:Prevalence; D011739:Pyrimethamine / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D005819:Genetic Markers; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine